Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 213-590-1 | CAS number: 991-84-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 974
- Report date:
- 1974
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- no data on test material purity, no neurotoxicological examination
- GLP compliance:
- no
Test material
- Reference substance name:
- 2,6-di-tert-butyl-4-(4,6-bis(octylthio)-1,3,5-triazin-2-ylamino)phenol
- EC Number:
- 213-590-1
- EC Name:
- 2,6-di-tert-butyl-4-(4,6-bis(octylthio)-1,3,5-triazin-2-ylamino)phenol
- Cas Number:
- 991-84-4
- Molecular formula:
- C33H56N4OS2
- IUPAC Name:
- 2,6-di-tert-butyl-4-(4,6-bis(octylthio)-1,3,5-triazin-2-ylamino)phenol
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Bred on own premises
- Weight at study initiation: Mean of males 197 g and females 159 g
- Housing: Rats were caged in groups of 5
- Diet: Commercial diet, ad libitum (Dakes Special Diet with added Vitamine E) to which the compound was added
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 +/- 2
- Humidity (%): 50 +/- 10
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- DIET PREPARATION
- Rate of preparation of diet (frequency): Freshly each week
- Mixing appropriate amounts with (Type of food): Powdered diet was mixed with dry extract of malt (Diamalt C) in the ratio of 85 % food to 15 % malt extract by weight. A premix of powdered diet and compound was prepared for each dose level. The premix was then thoroughly mixed with the bulk diet to produce the required concentrations of the test substance. 15 % Water was added and the mixture passed through a mincer. The pellets so produced were dried for approximately 12 hours at a temperature not exceeding 45°C. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- 8 g pulverised rat diet containing the test substance were extracted for 16 hours with benzene. The quantitative determination of the test compound in the food-extract was realised by spectrophotometry. Within the limits of error of the sampling technique and the analytical method there was good correspondence between the concentrations found in the diets and the nominal values.
- Duration of treatment / exposure:
- 91 days
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 5 000 ppm
- Remarks:
- corresponding to 311 mg/kg bw
- Dose / conc.:
- 10 000 ppm
- Remarks:
- corresponding to 694.5 mg/kg bw
- Dose / conc.:
- 20 000 ppm
- Remarks:
- corresponding to 1297.3 mg/kg bw
- No. of animals per sex per dose:
- 15, additional 5 males and females of the control group and the 20000 ppm dose group for the recovery group.
- Control animals:
- yes, plain diet
- Details on study design:
- - Post-exposure recovery period in satellite groups: 4 weeks with each 5 males and females from the control group and the 20000 mg/kg bw group
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: Weekly
FOOD CONSUMPTION AND COMPOUND INTAKE:
- Food consumption for each dose group determined and mean weekly diet consumption calculated: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Pretest (all animals), during weeks 5, 9, and 13 (10 each sex of the control group and the 20000 ppm dose group), and in week 17 all animals of the recovery group.
- Dose groups that were examined: See above
HAEMATOLOGY: Yes
- Time schedule for collection of blood: In weeks 5, 9, and 13 and in the recovery period (week 17)
- Anaesthetic used for blood collection: No data
- Animals fasted: No data
- How many animals: All animals of the control group and the 20000 ppm dose group and 5 males and females of the 5000 and 10000 ppm dose group.
- Parameters checked: Haemoglobin (Hb), Erythrocytes, Haematocrit, Inclusion bodies, Thrombocytes, Leucocytes (total count and differential count), Prothrombin Time
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: In weeks 5, 9, and 13 and in the recovery period (week 17)
- Animals fasted: No data
- How many animals: All animals of the control group and the 20000 ppm dose group and 5 males and females of the 5000 and 10000 ppm dose group.
- Parameters checked: Glucose, Urea, Serum Glutamic Oxaloacetic Transaminase (S.G.O.T.), Serum Glutamic Pyruvic Transaminase (S.G.P.T.), Serum Alkaline Phosphatase (S.A.P.)
URINALYSIS: Yes
- Time schedule for collection of urine: In weeks 5, 9, and 13 and in the recovery period (week 17)
- Metabolism cages used for collection of urine: No data
- Animals fasted: No data
- How many animals: All animals of the control group and the 20000 ppm dose group and 5 males and females of the 5000 and 10000 ppm dose group.
- Parameters checked: pH, Specific Gravity, Protein, Glucose, Bilirubin, Ketones, Blood, Urine Sediment
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (organ weights: Adrenals, Brains, Hearts, Kidneys, Livers, Gonads)
HISTOPATHOLOGY: Yes (Adrenals, Aorta, Bone marrow, Brain, Colon, Eye (+ optic nerve), Gonads, Gross lesions, Heart, Kidneys, Lymph nodes (axillary & mesenteric), Mammary gland, Muscle, Pancreas, Peripheral nerve (sciatic) Pituitary, Prostate, Small intestine, Spleen, Spinal cord, Stomach, Thymus, Thyroids, Urinary bladder, Uterus
Only for the control group and the high dose group histopathological examination was conducted.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No clinical symptoms were recorded.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Body weight gains were within normal limits and, in treated groups, comparable to controls.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Food consumption was within normal limits and, in treated groups, comparable to controls. The dose levels of 5000, 10000, and 20000 ppm were equivalent to an average daily intake of 311, 694.5 and 1297.3 mg/kg bw.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- Ophthalmic examination did not reveal any eye changes caused by treatment.
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- No significant differences were seen between the groups in respect of haematology parameters.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- No significant differences were seen between the groups in respect of clinical chemistry parameters.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- No significant differences were seen between the groups in respect of urine analysis parameters.
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Organ weights (both absolute and relative to brain) were comparable in all groups.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No changes referable to the administration of the test substance seen were seen at autopsy.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Thirty rats (15 males and 15 females) of the 20000 ppm dose group and of the control group, respectively, were examined in detail. The lungs of several rats in both groups showed evidence of mild chronic murine pneumonia and in many livers small fat droplets were seen in individual parenchymal cells in Sudan stained frozen sections. Spleens invariably showed moderate haemosiderosis and extra medullary haematopoiesis and nematode parasites were frequently observed in the lumen of the large intestine. Changes referable to the test substance were not found, as there was no significant difference in the incidence or severity of any of the above changes between test and control animals.
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- RECOVERY EXPERIMENT
No deaths and no clinical symptoms were recorded. Laboratory parameters were all within normal limits. Body weight gains and food consumption were within normal limits. The apparent fall in body weights of male animals in group 1 (control)
during the recovery period is due to the fact that the five animals had a lower average starting weight than the remainder of that group. No treatment induced changes were seen at autopsy. In view of the negative findings in group 4 (20000 p.p.m.) of the main study, no histopathological examination was carried out in group 5 (20000 p.p.m.).
Effect levels
- Dose descriptor:
- NOAEL
- Remarks:
- (systemic)
- Effect level:
- 1 297.3 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: The test compound administered in the diet to rats at a level of 20000 ppm (equivalent to an average daily intake of 1297.5 mg/kg) for 91 days did not cause any adverse effect.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Based on the results presented, the NOAEL was set at 1297.3 mg/kg body weight in rats, which was the highest concentration tested in this study.
- Executive summary:
The test article was administered in the diet to rats at levels of 0, 5000, 10,000 and 20,000 p.p.m. (equivalent to an average daily intake of 0, 311, 594.5 and 1297.3 mg/kg body weight), for not less than 91 days. No deaths occurred and no clinical symptoms were recorded. Body weight gains and food consumption were within normal limits and, in treated groups, comparable to controls.
No important differences were seen between groups in respect of haematology, clinical chemistry and urine analysis parameters.
Ophthalmic examination did not reveal any eye changes caused by treatment. Neither at autopsy nor on histopathological examination were any changes referable to the administration of the test item seen. Organ weights (both absolute and relative) were comparable in all groups. In the recovery group, no deaths and no clinical symptoms were recorded. Laboratory parameters were all within normal limits. Body weight gains anc food consumption were within normal limits. The apparent fall in body weights of male animals in group 1 (control) during the recovery period was due to the fact that the five animals had a lower average starting weight than the remainder of that group. No treatment induced changes were seen at autopsy. In view of the negative findings in group 4 (20,000 p.p.m.) of
the main study, no histopathological examination was carried out in group 5 (20,000 p.p.m.). Based on these findings, a NOAEL was set at 1297.3 mg/kg body weight in rats, which was the highest concentration tested in this study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.